[HTML][HTML] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Background Many countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
Effectiveness of a Third Dose of the BNT162b2 mRNA COVID-19 Vaccine for Preventing Severe Outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - The Lancet, 2021 - cris.bgu.ac.il
BACKGROUND: Many countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen… - Lancet (London …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Many countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
[PDF][PDF] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - Lancet, 2021 - scholar.archive.org
BackgroundMany countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
[HTML][HTML] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - The Lancet, 2021 - thelancet.com
Background Many countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
[引用][C] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - The Lancet, 2021 - cir.nii.ac.jp
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe
outcomes in Israel: an observational study | CiNii Research CiNii 国立情報学研究所 学術情報 …
outcomes in Israel: an observational study | CiNii Research CiNii 国立情報学研究所 学術情報 …
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - The Lancet, 2021 - Elsevier
Background Many countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
[PDF][PDF] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - 2021 - thedeeping.eu
BackgroundMany countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
[PDF][PDF] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - Lancet, 2021 - binasss.sa.cr
BackgroundMany countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
[PDF][PDF] Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
N Barda, N Dagan, C Cohen, MA Hernán, M Lipsitch… - 2021 - ripe-tomato.org
BackgroundMany countries are experiencing a resurgence of COVID-19, driven
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …
predominantly by the delta (B. 1.617. 2) variant of SARS-CoV-2. In response, these countries …